Shalini Shenoy, M.D.  shenoy@wustl.edu

Profile picture
Professor of Pediatrics, Washington University in St. Louis
Hematology and Oncology

phone: (314) 454-6018

Clinical Interests

Dr. Shenoy's research interests are focused on stem cell transplants for non-malignant disorders, reduced intensity transplants, and the immunologic mechanisms of graft rejection, graft versus host disease (GVHD), and immune reconstitution following stem cell transplantation (SCT). These efforts are directed at making SCT safer and better tolerated by reducing associated toxicities, especially as it relates to non-malignant disorders such as hemoglobinopathy. She is the Prinicipal Investigator of national trials of unrelated donor transplantation for severe sickle cell disease termed the SCURT Trial (Bone Marrow Transplant Clinical Trials Network 0601, NHLBI) and thalassemia termed the URTH Trial (Thalassemia Clinical Research Network, NHLBI). Other clinical trials for additional non-malignant disorders such as bone marrow failure syndromes using alternative and minimally mismatched donors are also underway.

Education

  • MBBS, Kasturba Medical College1981
  • MD, Kasturba Medical College1985
  • MD, Louisiana State University Medical Center1991
  • MD, Washington University in St. Louis1996

Training

  • Residency in Pediatrics, Kasturba Medical College1982 - 1985
  • Residency in Pediatrics, Louisiana State University Medical Center1989 - 1991
  • Fellowship in Pediatric Hematology Oncology, Washington University in St. Louis1992 - 1996

Licensure and Board Certification

  • MO, MD
  • Pediatric Hematology Oncology

Honors and Awards

  • American Society of Histocompatibility and Immunogenetics Scholar Award2001 - 2001
  • Fred Saunders Lecture Award, CBMTG2012 - 2012
  • Teresa J Vietti MD Scholar in Pediatrics, Washington University School of Medicine in St. Louis2014 - Pres

Recent Publications view all (77)


  1. Chronic Granulomatous Disease-Associated IBD Resolves and Does Not Adversely Impact Survival Following Allogeneic HCT. J Clin Immunol. 2019;39(7):653-67.. PMID:31376032 
  2. Related and unrelated donor transplantation for β-thalassemia major: results of an international survey. Blood Adv. 2019;3(17):2562-70.. PMID:31471325  
  3. Effect of donor type and conditioning regimen intensity on allogeneic transplantation outcomes in patients with sickle cell disease: a retrospective multicentre, cohort study. Lancet Haematol. 2019;E Pub S2352-3026(19)30154-1. PMID:31495699 
  4. Hematopoietic Stem Cell Transplantation: A Neonatal Perspective. Neoreviews. 2019;20(6):e336-e345. PMID:31261097  
  5. Higher Risks of Toxicity and Incomplete Recovery in 13- to 17-Year-Old Females after Marrow Donation: RDSafe Peds Results. Biol Blood Marrow Transplant. 2019;25(5):955-964. PMID:30605731 
  6. Effect of Aging and Predonation Comorbidities on the Related Peripheral Blood Stem Cell Donor Experience: Report from the Related Donor Safety Study. Biology of Blood and Marrow Transplantation. 2019;25(4):699-711. doi:https://doi.org/10.1016/j.bbmt.2018.11.004  
  7. Functional and Radiologic Assessment of the Brain after Reduced-Intensity Unrelated Donor Transplantation for Severe Sickle Cell Disease: Blood and Marrow Transplant Clinical Trials Network Study 0601. Biol Blood Marrow Transplant.. 2019. PMID:30639825 
  8. The genetic landscape of severe combined immunodeficiency in the United States and Canada in the current era (2010-2018). J Allergy Clin Immunol. 2019;143(1):405-407. PMCID:PMC6322970  PMID:30193840 
  9. Related peripheral blood stem cell donors experience more severe symptoms and less complete recovery at 1-year compared to unrelated donors. haematol. 2018. doi:10.3324/haematol.2018.200121  
  10. Immune Reconstitution and Infection Patterns after Early Alemtuzumab and Reduced Intensity Transplantation for Nonmalignant Disorders in Pediatric Patients. Biol Blood Marrow Transplant. 2018. PMID:30321596 
  11. Reduced intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies: BMT CTN 1204 Blood. 2018;132(13):1438-1451. doi:https://doi.org/10.1182/blood-2018-01-828277  
  12. Outcomes of Measurable Residual Disease in Pediatric Acute Myeloid Leukemia before and after Hematopoietic Stem Cell Transplant: Validation of Difference from Normal Flow Cytometry with Chimerism Studies and Wilms Tumor 1 Gene Expression 2018;24(10):2040-2046. doi:https://doi.org/10.1016/j.bbmt.2018.06.010  
  13. Late Effects Screening Guidelines after Hematopoietic Cell Transplantation (HCT) for Hemoglobinopathy: Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT.  Biol Blood Marrow Transplant.. 2018;24(7):1313-21.. PMID:29653206 
  14. Hematopoietic stem cell transplantation for sickle cell disease: Progress and challenges. Pediatr Blood Cancer. 2018;e27263. PMID:29797658 
  15. Early Identification of Barriers and Facilitators to Self-Management Behaviors in Pediatric Patients With Sickle Cell Disease to Minimize Hematopoietic Cell Transplantation Complications. J Pediatr Oncol Nurs. 2018;35(3):199-209. doi:10.1177/1043454218762703  PMID:29577801 
  16. Influence of Age on Acute and Chronic GVHD in Children Undergoing HLA-Identical Sibling Bone Marrow Transplantation for Acute Leukemia: Implications for Prophylaxis. Biol Blood Marrow Transplant. 2018;24(3):521-528. PMID:29155316  
  17. Principles of alemtuzumab immunoablation in hematopoietic cell transplantation for non-malignant diseases in children: A review. Pediatr Transplant. 2018;22(2). doi:10.1111/petr.13142  PMID:29352515 
  18. Unrelated Donor Transplantation in Children with Thalassemia Using Reduced Intensity Conditioning - the URTH Trial. Biol Blood Marrow Transplant. 2018. PMID:29374585 
  19. Comment on: Acquired monosomy 7 myelodysplastic syndrome in a child with clinical features of dyskeratosis congenita and IMAGe association. Pediatr Blood Cancer. 2018;65(1). PMID:28834235 
  20. A Multicenter Retrospective Analysis Stressing the Importance of Long-Term Follow-Up after Hematopoietic Cell Transplantation for B-Thalassemia. Biol Blood Marrow Transplant. 2017;10:1695-1700. doi:10.1016/j.bbmt.2017.06.004  PMID:28627425 
  21. Relationship between Mixed Donor-Recipient Chimerism and Disease Recurrence Following Hematopoietic Cell Transplantation for Sickle Cell Disease. Biol Blood Marrow Transplant. 2017. PMID:28882446 
  22. Awareness of cord blood collection and the impact on banking. Pediatr Blood Cancer. 2017;64(7). PMID:28111924 
  23. Unrelated Umbilical Cord Blood Transplantation for Sickle Cell Disease Following Reduced-Intensity Conditioning: Results of a Phase I Trial. Biol Blood Marrow Transplant. 2017. PMID:28578010 
  24. Current Results and Future Research Priorities in Late Effects after Hematopoietic Stem Cell Transplantation for Children with Sickle Cell Disease and Thalassemia: A Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2017;23(4):552-561. PMID:28065838 
  25. The Second Pediatric Blood and Marrow Transplant Consortium International Consensus Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation: Defining the Unique Late Effects of Children Undergoing Hematopoietic Cell Transplantation for Immune Deficiencies, Inherited Marrow Failure Disorders, and Hemoglobinopathies. Biol Blood Marrow Transplant. 2017;23(1):24-29. PMCID:PMC5267609  PMID:27737772 
  26. A trial of unrelated donor marrow transplantation for children with severe sickle cell disease. Blood. 2016;128(21):2561-2567. PMCID:PMC5123194  PMID:27625358 
  27. Long-Term Follow-Up after Reduced-Intensity Conditioning and Stem Cell Transplantation for Childhood Nonmalignant Disorders. Biol Blood Marrow Transplant. 2016;22(8):1467-72. PMID:27164064 
  28. Response to: "Technology and Long-Term Health-Related Quality-of-Life Outcomes in Children with Nonmalignant Disorders after Reduced-Intensity Conditioning and Stem Cell Transplantation". Biol Blood Marrow Transplant. 2016. PMID:27343717 
  29. Unrelated donor stem cell transplantation for transfusion-dependent thalassemia. Ann N Y Acad Sci. 2016;1368(1):122-6. PMCID:PMC4870105  PMID:26999376 
  30. Successful matched sibling donor marrow transplantation following reduced intensity conditioning in children with hemoglobinopathies. Am J Hematol. 2015. doi:10.1002/ajh.24183  PMID:26348869 
  31. Alemtuzumab based reduced intensity transplantation for pediatric severe aplastic anemia. Pediatr Blood Cancer. 2015;62(7):1270-6. doi:10.1002/pbc.25458  PMID:25755151 
  32. Hematopoietic Cell Transplantation Using Reduced-Intensity Conditioning Is Successful in Children with Hematologic Cytopenias of Genetic Origin. Biol Blood Marrow Transplant. 2015. doi:10.1016/j.bbmt.2015.03.019  PMID:25840334 
  33. Late toxicity of a novel allogeneic stem cell transplant using single fraction total body irradiation for hematologic malignancies in children. J Pediatr Hematol Oncol. 2015;37(2):e94-e101. doi:10.1097/MPH.0000000000000272  PMCID:PMC4337424  PMID:25333837 
  34. Advances in unrelated and alternative donor hematopoietic cell transplantation for nonmalignant disorders. Curr Opin Pediatr. 2015;27(1):9-17. doi:10.1097/MOP.0000000000000179  PMCID:PMC4403859  PMID:25565572 
  35. Evidence-based focused review of the status of hematopoietic stem cell transplantation as treatment of sickle cell disease and thalassemia. Blood. 2014;123(20):3089-94; quiz 3210. doi:10.1182/blood-2013-01-435776  PMID:24511087 
  36. Transplantation for children with acute myeloid leukemia: a comparison of outcomes with reduced intensity and myeloablative regimens. Blood. 2014;123(10):1615-20. doi:10.1182/blood-2013-10-535716  PMCID:PMC3945869  PMID:24435046 
  37. Successful treatment of recurrent hyperhemolysis syndrome with immunosuppression and plasma-to-red blood cell exchange transfusion. Transfusion. 2014;54(2):384-8. doi:10.1111/trf.12258  PMID:23692505 
  38. Exposure of early pediatric trainees to blood and marrow transplantation leads to higher recruitment to the field. Biol Blood Marrow Transplant. 2013;19(9):1399-402. doi:10.1016/j.bbmt.2013.06.021  PMID:23838095 
  39. Challenges and opportunities for international cooperative studies in pediatric hematopoeitic cell transplantation: priorities of the Westhafen Intercontinental Group. Biol Blood Marrow Transplant. 2013;19(9):1279-87. doi:10.1016/j.bbmt.2013.07.006  PMID:23883618 
  40. Outcomes of allogeneic hematopoietic cell transplantation in patients with dyskeratosis congenita. Biol Blood Marrow Transplant. 2013;19(8):1238-43. doi:10.1016/j.bbmt.2013.05.021  PMCID:PMC3736557  PMID:23751955 
  41. Umbilical cord blood: an evolving stem cell source for sickle cell disease transplants. Stem Cells Transl Med. 2013;2(5):337-40. doi:10.5966/sctm.2012-0180  PMCID:PMC3667562  PMID:23580541 
  42. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med. 2012;367(16):1487-96. doi:10.1056/NEJMoa1203517  PMID:23075175 
  43. Human polyomaviruses in children undergoing transplantation, United States, 2008-2010. Emerg Infect Dis. 2012;18(10):1676-9. doi:10.3201/eid1810.120359  PMCID:PMC3471627  PMID:23017293 
  44. Unrelated donor cord blood transplantation for children with severe sickle cell disease: results of one cohort from the phase II study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). Biol Blood Marrow Transplant. 2012;18(8):1265-72. doi:10.1016/j.bbmt.2012.01.019  PMCID:PMC3618440  PMID:22343376 
  45. Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood. 2012;119(25):5989-95. doi:10.1182/blood-2011-11-393975  PMCID:PMC3383014  PMID:22566601 
  46. Ofatumumab for a rituximab-allergic child with chronic-relapsing paraneoplastic opsoclonus-myoclonus. Pediatr Blood Cancer. 2012;58(6):988-91. doi:10.1002/pbc.23187  PMID:21618414 
  47. Hematopoietic stem cell transplantation for sickle cell disease: current practice and emerging trends. Hematology Am Soc Hematol Educ Program. 2011;2011:273-9. doi:10.1182/asheducation-2011.1.273  PMID:22160045 
  48. Advancement of pediatric blood and marrow transplantation research in North America: priorities of the Pediatric Blood and Marrow Transplant Consortium. Biol Blood Marrow Transplant. 2010;16(9):1212-21. doi:10.1016/j.bbmt.2009.12.536  PMCID:PMC2891395  PMID:20079865 
  49. Severe sickle cell disease--pathophysiology and therapy. Biol Blood Marrow Transplant. 2010;16(1 Suppl):S64-7. doi:10.1016/j.bbmt.2009.10.001  PMCID:PMC2832723  PMID:19819341 
  50. Acquired monosomy 7 myelodysplastic syndrome in a child with clinical features suggestive of dyskeratosis congenita and IMAGe association. Pediatr Blood Cancer. 2010;54(1):154-7. doi:10.1002/pbc.22283  PMID:19760774 
  51. Early outcomes after allogeneic hematopoietic SCT in pediatric patients with hematologic malignancies following single fraction TBI. Bone Marrow Transplant. 2009;43(4):307-14. doi:10.1038/bmt.2008.327  PMCID:PMC2792985  PMID:19011666 
  52. Reduced-intensity conditioning is effective and safe for transplantation of patients with Shwachman-Diamond syndrome. Bone Marrow Transplant. 2008;42(3):159-65. doi:10.1038/bmt.2008.151  PMID:18500373 
  53. Safety, efficacy, and immune reconstitution after rituximab therapy in pediatric patients with chronic or refractory hematologic autoimmune cytopenias. Pediatr Blood Cancer. 2008;50(4):822-5. doi:10.1002/pbc.21264  PMID:17570702 
  54. Allogeneic hematopoietic cell transplantation (HCT) in Hurler's syndrome using a reduced intensity preparative regimen. Bone Marrow Transplant. 2008;41(4):349-53. doi:10.1038/sj.bmt.1705926  PMID:18026148 
  55. Stem cell transplantation in genetically linked regulatory T-cell disorders. Chem Immunol Allergy. 2008;94:211-9. doi:10.1159/000155089  PMID:18802350 
  56. Hematopoietic stem cell transplantation for childhood malignancies of myeloid origin. Bone Marrow Transplant. 2008;41(2):141-8. doi:10.1038/sj.bmt.1705961  PMID:18176616 
  57. Has stem cell transplantation come of age in the treatment of sickle cell disease? Bone Marrow Transplant. 2007;40(9):813-21. doi:10.1038/sj.bmt.1705779  PMID:17704797 
  58. A randomized double-blind trial of hydroxychloroquine for the prevention of chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2007;13(10):1201-6. doi:10.1016/j.bbmt.2007.06.012  PMID:17889357 
  59. Successful bone marrow transplantation for IPEX syndrome after reduced-intensity conditioning. Blood. 2007;109(1):383-5. doi:10.1182/blood-2006-05-025072  PMID:16990602 
  60. Granulocyte-colony-stimulating factor-mobilized prophylactic granulocyte transfusions given after allogeneic peripheral blood progenitor cell transplantation result in a modest reduction of febrile days and intravenous antibiotic usage. Transfusion. 2006;46(1):14-23. doi:10.1111/j.1537-2995.2005.00665.x  PMID:16398726 
  61. Safety and efficacy of enzyme replacement therapy in combination with hematopoietic stem cell transplantation in Hurler syndrome. Genet Med. 2005;7(2):143-6. doi:10.109701.GIM.0000154299.22120.6A  PMID:15714083 
  62. A novel reduced-intensity stem cell transplant regimen for nonmalignant disorders. Bone Marrow Transplant. 2005;35(4):345-52. doi:10.1038/sj.bmt.1704795  PMID:15592491 
  63. Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial. Leukemia. 2005;19(1):34-8. doi:10.1038/sj.leu.2403566  PMID:15510203 
  64. Hydroxychloroquine for the prevention of acute graft-versus-host disease after unrelated donor transplantation. Biol Blood Marrow Transplant. 2003;9(11):714-21. doi:10.1016/j.bbmt.2003.08.006  PMID:14652855 
  65. Donor CMV serostatus has no impact on CMV viremia or disease when prophylactic granulocyte transfusions are given following allogeneic peripheral blood stem cell transplantation. Blood. 2003;101(5):2067-9. doi:10.1182/blood-2002-07-2110  PMID:12406871 
  66. Antibodies to 70 kD and 90 kD heat shock proteins are associated with graft-versus-host disease in peripheral blood stem cell transplant recipients. Clin Exp Immunol. 2002;127(3):553-9. PMCID:PMC1906313  PMID:11966775 
  67. Defective apoptosis in lymphocytes and the role of IL-2 in autoimmune hematologic cytopenias. Clin Immunol. 2001;99(2):266-75. doi:10.1006/clim.2001.5017  PMID:11318598 
  68. Effect of leukocyte compatibility on neutrophil increment after transfusion of granulocyte colony-stimulating factor-mobilized prophylactic granulocyte transfusions and on clinical outcomes after stem cell transplantation. Blood. 2000;95(11):3605-12. PMID:10828051 
  69. Allogeneic peripheral blood stem cell transplantation following CD34+ enrichment by density gradient separation. Bone Marrow Transplant. 2000;25(12):1223-8. doi:10.1038/sj.bmt.1702427  PMID:10871725 
  70. Response to steroid therapy in autism secondary to autoimmune lymphoproliferative syndrome. J Pediatr. 2000;136(5):682-7. doi:10.1067/mpd.2000.105355  PMID:10802504 
  71. Light microscopic, immunophenotypic, and molecular genetic study of autoimmune lymphoproliferative syndrome caused by fas mutation. Pediatr Dev Pathol. 2000;3(1):101-9. PMID:10594139 
  72. Immune reconstitution following allogeneic peripheral blood stem cell transplants. Bone Marrow Transplant. 1999;23(4):335-46. doi:10.1038/sj.bmt.1701581  PMID:10100577 
  73. A single‐center experience using alemtuzumab, fludarabine, melphalan, and thiotepa as conditioning for transplantation in pediatric patients with chronic granulomatous disease Pediatric Blood & Cancer 2019; ePub October 10.. 
  74. Endpoints for Sickle Cell Disease Clinical Trials: Renal and Cardiopulmonary, Cure, and Low-Resource Settings Blood Advances 2019. 
  75. Analysis of graft-versus-host disease (GVHD) and graft rejection using MHC class I-deficient mice. Clin Exp Immunol 1998. 112(2):188-95. PMID:9649180 
  76. Long-term follow-up of high-risk allogeneic peripheral-blood stem-cell transplant recipients: graft-versus-host disease and transplant-related mortality. J Clin Oncol 1999. 17(3):806-12.. PMID:10071270 
  77. Hematopoietic stem-cell transplantation for sickle cell disease: current evidence and opinions. Ther Adv Hematol 2013. 4(5):335-44. PMID:24082994 
Last updated: 10/14/2019
© 2019 by Washington University in St. Louis
One Brookings Drive, St. Louis, MO 63130